PPARG and metabolic dysfunction-associated steatotic liver disease: PPARγ is also an important regulator of lipid metabolism, and clinical studies demonstrated that PPARγ agonists can significantly reduce hepatic steatosis and improve NAFLD symptoms (Skat‐Rørdam et al., 2019).